Sox4 Is a Key Oncogenic Target in C/EBPα Mutant Acute Myeloid Leukemia  by Zhang, Hong et al.
Cancer Cell
ArticleSox4 Is a Key Oncogenic Target
in C/EBPaMutant Acute Myeloid Leukemia
Hong Zhang,1,2 Meritxell Alberich-Jorda,1,2,3 Giovanni Amabile,1,2 Henry Yang,4 Philipp B. Staber,1,2,5
Annalisa Di Ruscio,1,2 Robert S. Welner,1,2 Alexander Ebralidze,1,2 Junyan Zhang,1,2 Elena Levantini,1,2,6
Ve´ronique Lefebvre,7 Peter J.M. Valk,8 Ruud Delwel,8 Maarten Hoogenkamp,9 Claus Nerlov,10 Jo¨rg Cammenga,11
Borja Saez,1,12,13 David T. Scadden,1,12,13 Constanze Bonifer,9 Min Ye,1,2,* and Daniel G. Tenen1,4,*
1Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02215, USA
2Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
3Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic
4Cancer Science Institute, National University of Singapore, Singapore 117599, Singapore
5Division of Hematology and Hemostaseology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna 1090, Austria
6Institute of Biomedical Technologies, National Research Council, Pisa 56124, Italy
7Department of Cellular and Molecular Medicine, Orthopaedic and Rheumatologic Research Center, Cleveland Clinic Lerner Research
Institute, Cleveland, OH 44195, USA
8Erasmus University Medical Center, Rotterdam 3015 GE, the Netherlands
9School of Cancer Sciences, Institute of Biomedical Research, University of Birmingham, Birmingham B15 2TT, UK
10MRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK
11Department of Molecular Medicine and Gene Therapy and Department of Hematology, Lund University, Lund 22184, Sweden
12Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
13Stem Cell and Regenerative Biology Department, Harvard University, Cambridge, MA 02138, USA
*Correspondence: mye@bidmc.harvard.edu (M.Y.), csidgt@nus.edu.sg (D.G.T.)
http://dx.doi.org/10.1016/j.ccr.2013.09.018SUMMARYMutation or epigenetic silencing of the transcription factor C/EBPa is observed in 10% of patients with
acute myeloid leukemia (AML). In both cases, a common global gene expression profile is observed, but
downstream targets relevant for leukemogenesis are not known. Here, we identify Sox4 as a direct target
of C/EBPawhereby its expression is inversely correlatedwith C/EBPa activity. Downregulation of Sox4 abro-
gated increased self-renewal of leukemic cells and restored their differentiation. Gene expression profiles of
leukemia-initiating cells (LICs) from both Sox4 overexpression andmurine C/EBPamutant AMLmodels clus-
tered together but differed from other types of AML. Our data demonstrate that Sox4 overexpression result-
ing from C/EBPa inactivation contributes to the development of leukemia with a distinct LIC phenotype.INTRODUCTION
Acute myeloid leukemia (AML) is characterized by a differ-
entiation block and aberrant clonal growth of hematopoietic
blasts. It has been classified into individual subtypes with
respect to morphology, immunophenotype, and genetic abnor-
malities. In recent years, genome-wide gene expression
profiling has further identified distinct subsets (Valk et al.,
2004), which may reflect the underlying biology of these sub-
types and potentially reveal critical downstream targets for ther-
apeutic intervention.Significance
The alteration of the activity of transcription factors crucial for
their target genes is a recurrent pattern in leukemia. However, th
still poorly understood. This also holds true for AML with loss o
of transcriptional repression by C/EBPa and functionally valid
provide an explanation for the high levels of SOX4 expression
and highlight SOX4 as a potential therapeutic target for a sub
CanTranscription factor CEBPA is differentially translated into two
isoforms of 42 kDa and 30 kDa (Lin et al., 1993). Two-thirds of
AML cases with acquired point mutations of CEBPA have one
allele harboring N-terminal frame-shift mutations leading to
increased 30 kDa isoform and the other allele harboring C-termi-
nal in-frame insertions or deletions resulting in deficient DNA-
binding and/or homodimerization activities (Gombart et al.,
2002; Pabst et al., 2001). CEBPA double-mutant cases and
cases where CEBPA has been epigenetically silenced demon-
strate similar gene expression signatures, suggesting a common
mechanism of disease (Valk et al., 2004).blood cell development with a concomitant deregulation of
e precise nature and the role of their downstream targets are
f C/EBPa activity. Here, we identified Sox4 as a direct target
ated it as a central mediator of C/EBPa deficiency. Our data
in a human AML subtype carrying mutated or silent CEBPA
type of AML with currently limited therapeutic options.
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Sox4 Drives C/EBPa Mutant AMLC/EBPa regulates the expression of myeloid lineage-specific
genes and cell-cycle regulators, affect the self-renewal and
myeloid lineage commitment of hematopoietic stem cells
(HSCs), and induce growth arrest (Nerlov, 2004). However, the
30 kDa isoform fails to induce differentiation of granulocytes
and to block cell proliferation (Nerlov, 2004). Cebpa knockout
mice die at birth with a complete lack of mature granulocytes,
while adult mice with induced loss of C/EBPa demonstrate a
block from common myeloid progenitors (CMP) to granulocyte
monocyte progenitors (GMP) and accumulation of myeloid
blasts (Ye et al., 2013; Zhang et al., 2004). Knockin mice carrying
engineered biallelic CEBPA mutations as found in human AML
developed leukemia (Bereshchenko et al., 2009), but the keymo-
lecular downstream events required to trigger leukemogenesis
remain unclear.
Sox4 belongs to the Sox (SRY-related HMG-box) transcription
factor family (Jafarnejad et al., 2013). T cell development inSox4-
deficient embryos is severely impaired (Kuwahara et al., 2012),
and mice receiving Sox4/ fetal liver cells exhibit a block at
the pro-B cell stage (Schilham et al., 1996). SOX4 is upregulated
in various types of human solid tumors and is a frequent target of
retroviral insertional mutagenesis in many murine B cell lym-
phoma and myeloid leukemia models (Jafarnejad et al., 2013).
Its overexpression is associated with clonal dominance of HSC
(Kustikova et al., 2007), stem/progenitor cell repopulation advan-
tage (Deneault et al., 2009), a block in differentiation of myeloid
progenitor 32DCl3 cells (Boyd et al., 2006), and induction of
myeloid leukemia (Du et al., 2005; Kvinlaug et al., 2011). How-
ever, the precise role of Sox4 gene in AML and how it is involved
in specific AML subtypes is poorly understood.
RESULTS
A shRNA Screen Identifies Sox4 as a Mediator of
Enhanced Replating Ability and Decreased
Differentiation of Cebpa-Deficient Cells in Culture
Previous studies have revealed that disruption of C/EBPa in the
hematopoietic system resulted in abnormal expansion and an
altered transcription program of hematopoietic stem cells (Ye
et al., 2013; Zhang et al., 2004). To identify the downstream
effectors, we performed genome-wide gene expression profiling
and verified expression changes of the top 30 candidates of up-
regulated genes upon loss of C/EBPa in LSK cells (LinSca1+c-
kit+) (Figure 1A; Table S1 available online). We then functionally
evaluated the effect of knocking down these genes on Cebpa
KO cells (Mx1-Cre+ CebpaloxP/loxP; from here on referred to as
Cebpa KO following Cre-mediated deletion) after serially replat-
ing in methylcellulose cultures, a cell culture assay that has been
correlated with the ability to induce leukemia in mice (Huntly
et al., 2004; Lavau et al., 1997; Moran-Crusio et al., 2011). We
transduced Cebpa KO LSK cells with lentiviruses carrying either
a mix of scrambled small hairpin RNA (shRNA) (control) or a pool
of five shRNAs all targeting one specific candidate and assessed
their capability to undergo serial replating (Figure S1A). Among
the 30 candidates, shRNA-mediated knockdown of Sox4 ex-
hibited the strongest reduction of serial replating capability of
Cebpa KO LSK cells, with only a few colonies formed after two
rounds of replating and none at the fourth round, while scram-
bled controls maintained colony formation even after four rounds576 Cancer Cell 24, 575–588, November 11, 2013 ª2013 Elsevier Incof replating (Figures 1B and S1B). Moreover, Sox4 shRNA-trans-
duced Cebpa KO LSK cells differentiated into macrophages
(Figure 1C), as compared to morphologically immature control
colonies (aberrantly differentiated leukemic blast cells). Flow
cytometry analysis also revealed significantly increased expres-
sion of themature myeloid marker Mac1 (Figure 1D). Genotyping
PCR results confirmed complete excision of Cebpa alleles in
these cells (Figures S1C and S1D).
Because knocking down of Sox4 impaired the outgrowth
capability of Cebpa KO cells, we asked if Sox4 overexpression
was sufficient to confer replating ability to wild-type cells. We
therefore overexpressed Sox4 in wild-type LSK and progenitor
cells (common myeloid and granulocyte-macrophage progeni-
tors) and again performed serial replating assays. Aberrant
Sox4 expression resulted in enhanced replating ability for more
than four rounds in all tested cell types (Figures 1E and S1E).
Moreover in cytokine-supplemented myeloid liquid culture of
Sox4 transduced cells, myeloid differentiation was impaired (Fig-
ures 1F and S1F).
Collectively, our experiments identified the oncogene Sox4 as
a factor mediating increased serial-replating ability and blocked
differentiation of Cebpa-deficient progenitors.
Sox4 Expression Is Directly Regulated by C/EBPa
To understand the precise regulatory interaction betweenCebpa
and Sox4 during hematopoiesis, we examined their expression
patterns during different stages of blood cell differentiation.
Quantitative PCR (qCPR) analysis of adult wild-type mice
revealed that expression of Cebpa increased from SLAM+-
HSC (enriched for HSCs), LSK cells (enriched for both HSCs
and multipotent progenitors), common myeloid progenitors
(CMP) to granulocyte-macrophage progenitors (GMP), and
finally dropped in mature myeloid cells (Mac1+Gr1+) (Figure 2A).
In contrast, Sox4 demonstrated an inverse expression pattern
during myeloid lineage commitment, with highest expression in
LSK, and gradually decreasing toward myeloid maturation with
barely detectable levels in terminally differentiated myeloid cells
(Mac1+Gr1+) (Figure 2A).
Wenext examinedwhether the reciprocal expression ofCebpa
and Sox4 during myeloid commitment was due to a direct tran-
scriptional repression of Sox4 by C/EBPa. Chromatin immuno-
precipitation sequencing (ChIP-seq) analysis of murine bone
marrow derived primary macrophages indeed revealed two
adjacent C/EBPa-binding regions upstream of the murine Sox4
gene (Figure S2A). A major binding region was approximately
500 bp upstream of the Sox4 transcriptional start site (TSS)
(500 bp+1 bp relative to TSS) and a minor one was observed
within the 50 UTR region of Sox4 open reading frame
(+1 bp+200bp relative to TSS) (Figures 2BandS2A). Luciferase
assays using a reporter carrying a DNA fragment with the Sox4
promoter (500 bp to 889 bp relative to the TSS) revealed that
C/EBPa repressed the transcription activity from the Sox4 pro-
moter in a dose-dependent manner (Figure 2B). Such repression
was not due to the cellular saturation or toxicity of C/EBPa pro-
tein, since a parallel experiment indicated that within a similar
dose range, C/EBPa transactivated a luciferase reporter carrying
six consensus C/EBPa binding sites (Figure S2B).
Previous studies from our laboratory demonstrated that
C/EBPa inhibitsMyc andCebpg transcription through interfering.
Figure 1. Sox4 Is Required for Abnormal Serial-Replating Ability and Myeloid Differentiation Block of Cebpa KO Stem/Progenitor Cells
(A) Sox4 expression was analyzed by qPCR in LSK cells (Linc-kit+Sca1+) sorted from Mx1-Cre CebpaloxP/loxP (WT) and Mx1-Cre+ CebpaloxP/loxP (KO) mice
14 days after polyI:C injection. Relative gene expression levels were determined as % Gapdh.
(B) Cebpa KO LSK cells were transduced with lentiviruses harboring either scrambled shRNAs or Sox4 shRNAs and replated in methylcellulose plus puromycin.
The bar chart shows the colony number for four rounds.
(C) Wright-Giemsa staining of cells from the first plating round in Figure 1B. Data are representative of three independent experiments. Macrophages are
indicated with arrows. Scale bar, 20 mm.
(D) Flow cytometry analysis of cells from the first plating round in Figure 1B. The shadow histogram indicates scrambled shRNA-infected cells, and the black line
indicates Sox4 shRNA-infected cells. Percent cells are shown for the indicated gates. Data are representative of three independent experiments.
(E) Wild-type LSK, CMP (Linc-kit+Sca1CD34+FcRgII/IIIlo), and GMP (Lin-c-kit+Sca1-CD34+FcRgII/IIIhigh) were transduced with an empty retrovirus (Vector) or a
retrovirus expressing Sox4 (Sox4) and replated as Figure 1B.
(F) Wild-type LSK cells were transduced as in Figure 1E and grown in liquid culture plus puromycin and cytokines. Seven days later, Mac1 (left) and Gr1 (right)
expression was analyzed by flow cytometry. Shadow histograms indicate cells infected with empty virus, and black lines indicate cells overexpressing Sox4.
Percent cells are shown for the indicated gates. Data are representative of three independent experiments.
Error bars indicate the mean ± SEM of three independent experiments. **p < 0.001. See also Figure S1 and Table S1.
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Figure 2. Sox4 Is a Direct Target of Repression by C/EBPa
(A) qPCR analysis ofCebpa (top) andSox4 (bottom) levels in SLAM+-LSK, LSK,
CMP, GMP, and myeloid cells (Mac1+Gr1+). Relative gene expression levels
were determined as % Gapdh.
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578 Cancer Cell 24, 575–588, November 11, 2013 ª2013 Elsevier Incwith E2F1 transactivation on these promoters (Alberich-Jorda`
et al., 2012; Johansen et al., 2001). We therefore first examined
whether C/EBPa mediated Sox4 repression through a similar
mechanism. However, luciferase assays revealed that neither
E2F1 nor other E2F family members were able to activate the
Sox4 promoter (Figures S2C and S2D), although they were all
fully capable of transactivating a reporter carrying consensus
E2F binding sites. Increasing the amount of E2F1 did not antag-
onize the repression of Sox4 promoter by C/EBPa (Figure S2E).
Furthermore, to determine whether C/EBPa-mediated repres-
sion of E2F1 activity suppressed Sox4 mRNA expression, we
transduced Cebpa KO LSK cells with either wild-type Cebpa or
a series of Cebpa mutants (Porse et al., 2001). These experi-
ments showed that C/EBPa mutants BRM2 and BRM5, which
were defective in inhibiting E2F1-dependent transcription but
still bound efficiently to C/EBPa sites, still repressed aberrant
Sox4 expression in Cebpa KO LSK cells at levels comparable
to that of wild-type C/EBPa (Figure S2F). In these experiments,
C/EBPa wild-type and mutant constructs were expressed at
similar levels (Figure S2F). Taken together, these observations
ruled out a role of E2F1 in the repression of Sox4 by C/EBPa.
The Sox4 promoter contains multiple C/EBPa binding sites.
We therefore asked whether C/EBPa repressed the Sox4 pro-
moter through direct DNA binding. We generated a series of
truncation mutants of the Sox4 promoter corresponding to the
location of the putative C/EBPa binding sites (Figures 2C and
S2G). Luciferase assays with these truncation mutants revealed
that a fragment between 183 bp and 83 bp upstream of the(B) Top: schematic representation of the Sox4 promoter extending from
500 bp to +889 bp relative to TSS of murine Sox4 gene. Triangles denote the
ChIP-Seq C/EBPa binding peaks as shown in Figure S2A. Bottom: HEK293
cells were transfected with the Sox4 promoter reporter and increasing
amounts of pCDNA3-C/EBPa. Luciferase activities were normalized to Renilla
activities and presented as percentage of empty vector.
(C) Left: schematic representation of truncated constructs of the Sox4 pro-
moter reporter. Right: luciferase values of reporter constructs with an empty
vector (white bar) or C/EBPa-expressing constructs (black bars).
(D) Electrophoretic mobility shift assay using a probe containing a potential C/
EBPa binding site from the Sox4 promoter was performed with nuclear
extracts from HEK293T cells overexpressing Flag-tagged C/EBPa (HEK293T/
C/EBPa-Flag) and Flag antibody (anti-Flag) or C/EBPa antibody (anti-C/EBPa).
C/EBPa, C/EBPa complex; ss, supershifted band; x, migration of nonspecific
protein complexes binding to the probes.
(E) Left: schematic representation of luciferase reporters carrying wild-type
Sox4 promoter (WT) or Sox4 promoter with mutated C/EBPa binding sites [C/
EBPa(m)] marked with a cross. The putative C/EBPa binding sites and the
mutated version are underlined. Right: luciferase values of reporter constructs
carrying wild-type or site-mutated Sox4 promoter with an empty vector (white
bar) or C/EBPa-expressing constructs (black bars).
(F) ChIP-qPCR analysis of specific binding of C/EBPa to the upstream prox-
imal region of murine Sox4 gene in wild-type primary stem/progenitor cells
(Linc-kit+) or myeloid cells (Mac1+Gr1+). Top: schematic of Sox4 gene with
three qPCR primer sets (arrows below). Oval denotes the C/EBPa binding site
identified in Figure 2E. Primer sets ‘‘mSox4-1’’ and ‘‘mSox4-2’’ were used to
amplify regions 171 to +77 bp and 215 to 16 bp (relative to the TSS) of
Sox4 gene and primer set ‘‘NC’’ were used as a negative control. Bottom:
relative DNA enrichment was measured by qPCR and is presented as per-
centage of input chromatin. Black bars represent ChIP-qPCR signals from the
C/EBPa pull-down (C/EBPa) while white bars are from immunoglobulin G
control (IgG).
Error bars indicate the mean ± SEM of three independent experiments. *p <
0.01; **p < 0.001. See also Figure S2.
.
Figure 3. Sox4 Mediates the Aberrant Progenitor Expansion
following Loss of C/EBPa
(A) Flow cytometry analysis of LSK frequency (Linc-kit+Sca1+) in bone
marrow of Mx1-CreSox4loxP/loxPCebpaloxP/loxP (WT), Mx1-Cre+Sox4loxP/loxP
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CanSox4 TSS was essential for C/EBPa-mediated repression (Fig-
ure 2C). EMSA combined with supershift assay and competitor
assay further revealed specific association of C/EBPa protein
with potential cis elements at 174 bp to 150 bp upstream of
the Sox4 TSS (Figures 2D and S2H). Mutation of a highly evolu-
tionally conserved C/EBPa binding site in this region resulted in
loss of repression of the Sox4 promoter by C/EBPa (Figures 2E
and S2I). To further verify direct binding of C/EBPa to the identi-
fied region within the Sox4 promoter, we performed ChIP assays
on primary cells isolated from adult wild-type mice. Using two
sets of primers amplifying the 18383 bp region (relative to
the TSS), we confirmed binding of endogenous C/EBPa to this
region in both a stem/progenitor cell enriched population
(Linc-kit+) and mature myeloid cells (Mac1+Gr1+) (Figure 2F).
Moreover, the binding of C/EBPa was specific to this region,
since no enrichment of a distal region of the Sox4 gene was
observed. In summary, our data demonstrate that C/EBPa nega-
tively regulates Sox4 transcription via direct DNA binding.
Sox4 Mediates the Abnormal Expansion of LSK Cells in
the Absence of C/EBPa In Vivo
To functionally dissect the role in which dysregulated Sox4
expression is contributing to the Cebpa knockout phenotype
in vivo, we designed an inducible Sox4/Cebpa double-knockout
model. We generated conditional Sox4-deficient mice alone
(Mx1-Cre+ Sox4loxP/loxP; referred to as Sox4 KO following Cre-
mediated deletion) (Penzo-Me´ndez et al., 2007) and inducible
Sox4/Cebpa double knockouts (Mx1-Cre+ Sox4loxP/loxP
Cebpa loxP/loxP; referred to as dKO after deletion) (Figure S3A).
Flow cytometry analysis of bone marrow frommice 21 days after
induction of Cre recombinase-mediated deletion with polyI:C
demonstrated that Cebpa KO mice exhibited a remarkable
expansion of LSK cells, both in terms of percentage of total
bone marrow (4-fold; Figure 3A) and in absolute number (18-
fold; Figure 3B). LSK cells in Sox4 KO mice did not display any
gross phenotypical differences compared to wild-type LSKs
(Figures 3A and 3B). However, in concordancewith the opposingCebpa+/+ (Sox4 KO), Mx1-Cre+Sox4+/+CebpaloxP/loxP (Cebpa KO), and Mx1-
Cre+Sox4loxP/loxPCebpaloxP/loxP (dKO) mice 21 days after polyI:C treatment.
Representative fluorescence-activated cell sorting (FACS) plots of six inde-
pendent experiments are shown.
(B) Comparison of LSK cell number in the bone marrow of WT, Sox4 KO,
Cebpa KO, and dKO mice. Numbers are presented as fold change relative to
the WT.
(C) Flow cytometry of BrdU incorporation in LSK cells of single and double
knockouts. Percent BrdU+ cells are shown for the indicated gates. One
representative experiment of three is shown.
(D) Quantitative analysis of BrdU incorporation in LSK cells of single and
double knockouts.
(E) qPCR analysis of Ccnd1, Bmi1, and Mycn expression in LSK cells from
single and double knockouts. Relative mRNA levels were determined as %
Gapdh.
(F) Flow cytometry analysis of donor-derived LSK frequency (CD45.2+Lin-
c-kit+Sca1+) in the bone marrow of recipient mice transplanted with LSK cells
from mice with indicated phenotypes. Analysis was performed 4 months
posttransplantation. One representative recipient of ten recipients is shown.
(G) Quantitative analysis of donor-derived LSK frequency in the bone marrow
of recipient mice.
Error bars indicate the mean ± SEM of three independent experiments. *p <
0.01; **p < 0.001. See also Figure S3.
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Sox4 Drives C/EBPa Mutant AMLroles of Sox4 and C/EBPa, LSK expansion of Cebpa KO mice
was partially rescued in dKO mice with a 2-fold proportional
(Figure 3A) and a 3-fold absolute reduction in LSK numbers
(Figure 3B).
We next assessed the impact of C/EBPa and Sox4 on LSK
proliferation utilizing 5-bromodeoxyuridine (BrdU) incorporation
in vivo. The proliferative fraction of LSKs was remarkably
enhanced (4-fold) in Cebpa KO mice but was lower in the
dKO mice, comparable to wild-type (Figures 3C and 3D). Gene
expression analysis further identified several candidate genes
potentially mediating the differences in proliferation between
Cebpa KO and dKO LSK cells (Figures 3E, S3B, and S3C). In
Cebpa KO LSK cells, among the major cell-cycle regulators,
Cnnd1 was upregulated whereas p21 and p57 (Pietras et al.,
2011) were downregulated compared to the wild-type and
Sox4 KO counterparts. Increased expression was also observed
for Bmi1 andMycn, both of which are implicated in HSC prolifer-
ation and self-renewal in the absence of C/EBPa (Ye et al., 2013;
Zhang et al., 2004). However, the additional disruption of Sox4
significantly impeded such deregulation in the dKO LSK cells,
providing a putative molecular mechanism of how Sox4 induce
LSK expansion in Cebpa KO mice.
To investigate if Sox4 modulates the Cebpa KO HSC pheno-
type in a cell-intrinsic manner, LSK cells from wild-type mice
or conditional deficient mice (CD45.2+) 21 days post-polyI:C
injection were transplanted into lethally irradiated recipients
(CD45.1+). Four months after transplantation, flow cytometry
confirmed aberrant LSK expansion in recipients of Cebpa KO
LSK cells and a partial rescue in recipients of dKO LSK cells (Fig-
ures 3F and 3G). Genotyping of LSK cells isolated from the
conditional deficient mice or donor-derived LSK cells isolated
from the recipients verified complete excision of the Cebpa
and Sox4 alleles (Figures S3D–S3F). These data demonstrate
an HSC cell-intrinsic role for Sox4 on proliferation induced by
loss of C/EBPa.
Targeting Sox4 Restores Myeloid Differentiation of
Cebpa KO Cells In Vivo
Knockdown of Sox4 enables Cebpa KO LSK cells to undergo
myeloid differentiation in vitro (Figures 1C and 1D). To test the
effect of Sox4 on the impaired myeloid differentiation of Cebpa
KO LSKs in vivo, we examined whether the disruption of Sox4
could restore myeloid differentiation in Cebpa KO mice. Flow
cytometry analysis of bone marrow cells from wild-type or Sox4
KOmice 21-day post-polyI:C injection revealed a similar propor-
tion of Mac1+Gr1+ myeloid cells, whereas in Cebpa KO mice the
myeloid population was barely detectable (Figure S4A; deletion
efficiency shown in Figure S4B). Although a Mac1lo/+Gr1 popu-
lation appeared in the dKO mice, they were morphologically
immature blasts, as with the Mac1Gr population (data not
shown).
In contrast, dKO LSK cells were able to give rise to a significant
population of mature myeloid (Mac1+Gr1+) 4 months following
transplantation (Figures 4A and 4B). Cytology of sorted donor-
derived Mac1+Gr+ cells confirmed the presence of morphologi-
cally differentiatedmaturemyeloid cells, similar towild-type cells
(Figure 4C). Genotyping analysis confirmed complete excision of
Cebpa and Sox4 in the donor-derived Mac1+Gr1+ population
(Figure S4C).580 Cancer Cell 24, 575–588, November 11, 2013 ª2013 Elsevier IncWe also transplanted Cebpa KO LSK cells that had been
transduced with GFP containing retroviruses expressing either
Sox4 shRNAs (shRNA 672 and shRNA 928) or scrambled shRNA
(Figures S4D and S4E). Mature myeloid cells (Mac1+Gr1+) were
only present in the GFP+ donor population of mice receiving
Sox4 shRNA-transduced Cebpa KO LSK cells (Figures 4D
and 4E). Genotyping of donor-derived GFP+Mac1+Gr1+ cells
confirmed a complete excision of Cebpa allele (Figure S4F).
Taken together, these data demonstrate that the disruption of
Sox4 restores myeloid programming of Cebpa KO LSKs in vivo,
further substantiating the notion that Sox4 is epistatic to Cebpa.
Sox4 Is Crucial for the Oncogenic Activity of Mutated
C/EBPa
In a murine model of human AML expressing biallelic CEBPA
mutations (K/L mice), only a distinct phenotypically defined
group of cells (leukemia-initiating cells, or LICs) gives rise to leu-
kemia (Bereshchenko et al., 2009). To examine the role of Sox4
in those cells, we examined its expression in cellular subpopu-
lations of leukemic K/L mice and observed that Sox4 mRNA
was exclusively increased in the LIC fraction (fraction II: Lin*lo
Sca1Mac1loc-kit+), whereas it appeared to be decreased or
absent in the other fractions (fraction I: Lin*loSca1+; fraction
III: Lin*loSca1Mac1+c-kitlo/) (Figures 5A and S5A). It had
previously been shown that mice transplanted with Sox4-trans-
duced 5-FU treated bone marrow cells develop myeloid leuke-
mia (Du et al., 2005). We confirmed this result by transplanting
Sox4-transduced LSK cells and showed that mice died with a
median latency of 4 months (Figures S5B and S5C). Flow
cytometry revealed that Sox4-induced leukemia cells shared
key phenotypical features with the model for biallelic Cebpa
mutants (K/L leukemia; Figure 5B). Most importantly, as
described for K/L leukemia, in Sox4-induced leukemia, only
cells from fraction II gave rise to leukemia in recipient mice (Fig-
ures 5C and 5D).
To determine ifSox4 contributes to leukemogenesis not only in
Cebpa-deficient AML but also AML with mutated Cebpa, we
examined the effect of Sox4 ablation on the self-renewal ability
of K/L LICs. As with Cebpa KO cells, LICs from leukemic K/L
mice exhibited an enhanced replating ability (Figure S5D). In
addition, sorted K/L LIC cells were lentivirally transduced with
either scrambled shRNAs (f-1 and f-2) or Sox4 shRNAs (#80,
#81, and #82) (Figure S5E). Cells transduced with Sox4 shRNA
exhibited decreased ability to undergo serial replating and barely
gave rise to colonies in the second round of plating, while the
cells transducedwith scrambled shRNA still gave rise to colonies
even after the third round of plating (Figure 5E), demonstrating
that increased Sox4 levels are crucial for the self-renewal prop-
erties of Cebpa mutant LICs.
A Common Gene Expression Signature Defines Cebpa
KO, Sox4 AML, and K/L AML
Hierarchical clustering analysis of gene expression profiles
further revealed that the LIC populations from K/L and Sox4
murine leukemia models clustered together and were distinct
from their immunophenotypic counterparts (fraction II from
wild-type mice [WT FrII]) as well as from the leukemic stem
cell-enriched L-GMP from the MLL-AF9 and MOZ-TIF2 murine
AML models (MF9 L-GMP and MT2 L-GMP) (Krivtsov et al.,.
Figure 4. Loss of Sox4 Restores Myeloid
Differentiation ofCebpa-deficient LSKCells
In Vivo
(A) Flow cytometry analysis of donor-derived
myeloid cell (CD45.2+Mac1+Gr1+) in the bone
marrow of recipient mice transplanted with LSK
cells from mice with indicated phenotypes. Anal-
ysis was performed 4months posttransplantation.
Representative FACS plots of six independent
experiments are shown.
(B) Quantitative analysis of donor-derived myeloid
cell frequency in the bone marrow of recipient
mice. Error bars indicate the mean ± SEM of six
independent experiments. *p < 0.01.
(C) Wright-Giemsa staining of donor-derived
Mac1+Gr1+ cells in the bone marrow of recipient
mice. Granulocytic cells are indicated with arrows.
Scale bar, 10 mm.
(D) Flow cytometry analysis of donor-derived
myeloid cells in the bone marrow of mice receiving
Cebpa KO LSK cells transduced with scrambled
shRNA or mSox4 shRNA. The percentages
of Mac1+Gr1+ population within donor-derived
(CD45.2+) GFP+ and GFP cells are indicated.
Representative FACS plots of five independent
experiments are shown.
(E) Quantitative analysis of donor-derived shRNA-
transduced myeloid cell frequency (CD45.2+GFP+
Mac1+Gr1+) in the bone marrow of recipient mice.
Error bars indicate the mean ± SEM of five inde-
pendent experiments. p = 0.03.
See also Figure S4.
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Sox4 Drives C/EBPa Mutant AML2006; Kvinlaug et al., 2011) (Figure 6A). This suggested the exis-
tence of a common leukemogenic gene expression signature
characterizing Sox4 LIC and mutated C/EBPa LIC. Intriguingly,
Cebpa-deficient HSCs also clustered together with LICs from
K/L and Sox4 AML by sharing similar expression pattern of
686 genes, indicating underlying similarities among these three
populations. We next investigated whether our results from the
mousemodels were of relevance to human AML. Previous unsu-
pervised hierarchical gene expression clustering of leukemic
blasts from 562 AML patients identified a homogenous group
(cluster 4) in which both CEBPA-silenced and biallelic-mutated
cases clustered together (Valk et al., 2004). Intriguingly, SOX4
expression was significantly increased within the very same
group (Figure 6B), further confirming that SOX4 and mutated/
silenced CEBPA are within one oncogenic pathway.Cancer Cell 24, 575–588, NSupervised clustering analysis identi-
fied a set of genes that were highly ex-
pressed in the wild-type HSC and LIC
populations from Sox4 and K/L leuke-
mias but exhibited decreased expression
in committed progenitors (referred to as
‘‘self-renewal-associated LIC signature’’)
(Figure 6C; Table S2). We next compared
this signature with a previously reported
L-GMP self-renewal-associated signa-
ture (Krivtsov et al., 2006). This revealed
that only a very limited set of genes
crucial for acquisition of self-renewalproperties in L-GMP (24 out of 420) are present in the LICs
from Sox4 and K/L leukemias (24 out of 80) and the majority of
this self-renewal-associated LIC signature (56 genes) is specific
to the Sox4 and K/L leukemias (referred to as ‘‘specific C/EBPa-
Sox4 LIC signature’’) (Figures 6D and S6A; Tables S3, S4, and
S5). Within the specific C/EBPa-Sox4 LIC signature, two key
elements of TGFb-FOXO signaling that have been implicated in
maintaining LICs in chronic myeloid leukemia (Naka et al.,
2010), Foxo3a and type II TGFb receptor, are specifically upre-
gulated (Table S4). In addition, a set of genes whose upregula-
tion are functionally important for L-GMP transformation by
MLL-AF9 and MOZ-TIF2 (Krivtsov et al., 2006; Kvinlaug et al.,
2011) were either downregulated or unaltered in LICs, including
TCF4, CDKN1C, HoxA5, HoxA10, and Lmo2 (Figure 6E; Table
S5). These observations suggested a distinct transformationovember 11, 2013 ª2013 Elsevier Inc. 581
Figure 5. The LIC in Sox4-Induced AML Resembles the LIC in a Murine C/EBPa Mutant AML Model
(A) qPCR analysis of Sox4 expression in donor-derived fractions I (Lin*loSca1+), II (Lin*loSca1-Mac1loc-kit+) and III (Lin*loSca1Mac1+c-kitlo/) from wild-type
control (WT) or leukemic K/Lmice. Relative expression levels were determined as%Gapdh and presented as themean ± SEMof three independent experiments.
*p < 0.01.
(B) Flow cytometry analysis of mice transplanted with bone marrow from wild-type mice, K/L mice, or with LSK cells overexpressing Sox4. Total bone marrow
cells were subjected to lineage depletion excludingMac1 andGr1 (Lin*) followed by FACS analysis. Representative FACS plots of three independent experiments
are shown.
(C) Kaplan-Meier survival analysis of mice that received fractions I, II, and III from Sox4 leukemic mice. Number of recipients for each fraction (n) is
indicated.
(D) Flow cytometry analysis of mice that received fractions I, II, and III from Sox4 leukemic mice. Donor-derived cells (CD45.2+) in the bone marrow were analyzed
at indicated time points. Representative FACS plots of three independent experiments are shown.
(E) Donor-derived fractions II from leukemic K/L mice were transduced with either scrambled shRNAs or Sox4 shRNAs and serially replated. The bar chart shows
the mean ± SEM of colony number of three independent experiments.
See also Figure S5.
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L-GMPs and the LICs from Sox4 and K/L leukemias. On the
other hand,Mef2C (a cooperating oncogene in leukemogenesis)
(Du et al., 2005; Krivtsov et al., 2006) and prostaglandinendoper-
oxide synthase 1 (Ptgs1) (a key enzyme in Wnt/b-catenin
pathway-related prostaglandin synthesis) (Castellone et al.,
2005; Goessling et al., 2009) are upregulated in the self-
renewal-associated signature of both LICs and L-GMPs (Wang
et al., 2010) (Table S3). These observations suggested that
certain molecular pathways were commonly required for
leukemic transformation regardless of the underlying initiating
mutation of L-GMPs and LICs.
Gene set enrichment analysis (GSEA) further demonstrated
that the specificC/EBPa-Sox4 LIC signaturewas highly enriched
in gene expression profiles from human AML samples with bial-
lelicCEBPAmutation or silentCEBPA, but not in those of human
AML samples with wild-type CEBPA (Figures 6F and S6B),
supporting the relevance of the LIC signature identified from
the murine AML model in human AML.
Targeting SOX4 Rescues Myeloid Differentiation in
Human CEBPA Mutant AML
To functionally evaluate the relevance of our findings in murine
models to human leukemia, we first determined the ability of
leukemogenic human CEBPA mutations to repress Sox4 mRNA
expression. We analyzed Sox4 mRNA levels after transducing
Cebpa KO LSK cells with viruses encoding either wild-type hu-
man CEBPA or a series of mutant proteins identified from human
AML patients (Pabst et al., 2001). Interestingly, CEBPA mutant
proteins 22N, 22C, and 10, which exhibit an increased ratio of
30 kDa to 42 kDaCEBPA and are defective in DNA binding, failed
to repress Sox4, in contrast to wild-type human CEBPA (Fig-
ure 7A). Of note, CEBPA mutant 128, which exhibited the wild-
type 30 kDa to 42 kDa ratio and maintained the ability to bind
efficiently toC/EBPabinding sites,was still capable of repressing
Sox4 expression at levels comparable to those of wild-type
CEBPA (Figure 7A). In all of these experiments, CEBPA wild-
type andmutant constructs were expressed at similar levels (Fig-
ure S7A). We next analyzed the effects of individual CEBPA
mutant proteins onSox4 promoter activity using reporter assays.
Consistent with the findings of Sox4 mRNA expression analysis
(Figure 7A), DNA-binding defective CEBPA mutants (22N, 22C,
and 10) failed to repress Sox4 promoter activity (Figure 7B)
when expressed at comparable protein levels (Figure S7B).
Taken together, these data indicate that dysfunctional CEBPA
proteins known to underlay the development of human AML fail
to suppress SOX4.
To determine if targeting SOX4 could revert human CEBPA bi-
allelic mutant AML, we next studied the effect of SOX4 shRNA
knockdown in such cells in vivo. Two CEBPA mutant AML
patient samples were transduced with lentiviruses carrying a
GFPmarker and either SOX4 shRNA or a scrambled shRNA (Fig-
ure S7C). Transduced cells were then transplanted into suble-
thally irradiated NSGmice. Flow cytometry of bone marrow cells
5 weeks after transplantation revealed pronounced neutrophilic
differentiation as evidenced by CD15 surface marker expression
in the GFP+ population of SOX4 shRNA-transduced human
patient cells (Figure 7C). Furthermore, cytology of sorted GFP+
human cells (CD45+GFP+) showed the presence of matureCanneutrophils in SOX4 shRNA-transduced cells only (Figure 7D).
Taken together, downregulation of SOX4 in human CEBPA
mutant AML samples partially restores granulocytic differentia-
tion in vivo, thus providing strong experimental evidence that
enhanced SOX4 is a major contributor to the leukemic pheno-
type in human leukemia with dysfunctional CEBPA.
DISCUSSION
Sox4 Is a Central Mediator of AML with Defective
C/EBPa
In this study, we demonstrate that Sox4 contributes to the
leukemic phenotype of C/EBPa mutant AML in murine models
as well as in human AML. C/EBPa is both a transcription
activator and repressor, depending on the target genes and
cell context. As a tumor suppressor, C/EBPa modulates cell
growth through repression of oncogenes Myc, Mycn, and Bmi1
(Johansen et al., 2001; Ye et al., 2013; Zhang et al., 2004).
Here, we identified and validated Sox4 as a C/EBPa downstream
target.
Previous studies reported that Sox4 is upregulated in L-GMPs
from murine MOZ-TIF2, AML1-ETO, and NUP98-HOXA9 AML
models in an immediate leukemia initiation signature (Kvinlaug
et al., 2011). However, among 16 groups of AML patients classi-
fied on the basis of molecular signatures (Valk et al., 2004), SOX4
is only upregulated in AML subtypes carrying biallelic mutated
and silent CEBPA or internal tandem duplication mutation of
FLT3 (FLT3-ITD). Previous observations that FLT3-ITD blocks
C/EBPa through transcriptional repression or posttranslational
modification (Radomska et al., 2006; Zheng et al., 2004), and
that CEBPA biallelic mutant AML patients have a lower coinci-
dence of FLT3-ITD mutations (Green et al., 2010), suggest that
aberrant levels of SOX4 in FLT3-ITD subtypes is likely due to
CEBPA deficiency.
Previous studies based on knockin mice demonstrated that
biallelic Cebpa mutations induce leukemia by expanding stem/
progenitor cells with development of a transformed progenitor
pool blocked in myeloid differentiation (Bereshchenko et al.,
2009). Here, we demonstrate that dysregulated Sox4 contributes
to these leukemia phenotypes. Furthermore, the expansion of a
highly proliferative premalignant LSK compartment caused by
DNA-binding defective Cebpa mutations is alleviated in dKO
mice, suggesting that enhanced Sox4 levels are crucial to main-
tain this transformable pool. The exclusive increase of Sox4 level
in C/EBPa mutant LICs also suggests its potential role in LIC
function. Unfortunately, complete loss of LIC leukemogenic
potential after even a very short period of liquid culture precludes
addressing this issue by viral-mediated RNAi knockdown
followed by transplantation (Claus Nerlov and Jorg Cammenga,
personal communication [and confirmed by us]). However,
serial-replating assays, a surrogate for self-renewal potential
that has been validated with transplantation assays in a number
of studies (Huntly et al., 2004; Lavau et al., 1997; Moran-Crusio
et al., 2011), suggest a causative role for Sox4 in the acquisition
of LIC self-renewal.
Althoughmyelopoiesis in Sox4KOmice appears normal, Sox4
can inhibit myeloid differentiation in 32DCl3 cells (Boyd et al.,
2006) and primary stem/progenitor cells treated with cytokines,
consistent with the progressive decrease in Sox4 expressioncer Cell 24, 575–588, November 11, 2013 ª2013 Elsevier Inc. 583
Figure 6. Gene Expression Signatures of Sox4 and K/L LICs Are Distinct from MLL-AF9 and MOZ-TIF2 L-GMPs
(A) Hierarchical clustering of fraction II population from leukemic K/L and Sox4 recipients and their wild-type counterparts (WT FRII), L-GMP population from
leukemic MLL-AF9 and MOZ-TIF2 recipients, and HSCs from Cebpa KO mice (KO HSC).
(B) Pairwise correlations between CEBPA and SOX4 in gene expression profiles of human AML patients. The bar and histograms next to each sample indicate
CEBPA allele status (mutations are shown in red and wild-type are shown in green) and CEBPA and SOX4 mRNA expression levels. The black lines designate
cluster 4 AML patients with either mutated or silent CEBPA allele(s).
(C) Heatmap shows the 80-gene self-renewal-associated LIC signature that is specifically upregulated in the wild-type HSCs (versus committed progenitors) as
well as Sox4 and K/L LICs (versus WT FrII) (fold change cutoff = 1.5; p value cutoff = 0.05).
(D) The Venn diagram shows the overlap between the ‘‘self-renewal-associated LIC signature’’ (80 genes) and the ‘‘self-renewal-associated L-GMP signature’’
(420 genes) in a single two-class comparison. Shadow area indicates the ‘‘specific C/EBPa-Sox4 LIC signature’’ (56 genes).
(legend continued on next page)
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entiation. Our finding that suppression of Sox4 partially restored
myeloid differentiation of dKO LSK and human CEBPA mutant
AML samples further demonstrates that enhanced Sox4 expres-
sion blocks myeloid differentiation in this AML subtype. Collec-
tively, we demonstrate a central role of Sox4 in C/EBPa mutant
induced leukemogenesis.
Our findings in murine C/EBPa mutant AML suggest that
abrogation of SOX4 may also affect the function of LICs from
human CEBPA mutated or silent AML. However, a lack of
phenotypic definition of human CEBPA mutated/silent LICs
omitted further investigations, since LICs cannot be universally
defined for all AML samples on the basis of the CD34+CD38
phenotype (Eppert et al., 2011; Sarry et al., 2011; Taussig
et al., 2008, 2010).
Sox4 and C/EBPaMutant Leukemias Share a Unique
Gene Expression Signature
The overlap between gene expression patterns of Sox4 LICs, K/L
LICs, and Cebpa KO HSCs suggests the existence of a transfor-
mation signature specific to Sox4-mediated C/EBPa-defective
LICs that is distinct from that of L-GMPs from MLL-AF9 and
MOZ-TIF2 AML (Krivtsov et al., 2006; Kvinlaug et al., 2011).
This suggests that Sox4 and K/L LICs use different transforma-
tion pathways from MLL-AF9 and MOZ-TIF2 L-GMPs, a notion
further strengthened by very limited overlap between their self-
renewal signatures. Intriguingly, gene expression profile com-
parisons demonstrated increased Foxo3a and type II TGFb
receptor levels only in the specific C/EBPa-Sox4 LIC signature
and in human AML samples with mutated and silent CEBPA.
Although the exact role of this signaling cascade in AML remains
unknown, its relevance to LICs in CML has been demonstrated
(Naka et al., 2010). In a BCR-ABL-induced CMLmodel, pharma-
ceutical inhibition of TGFb-FOXO signaling in combination with a
tyrosine kinase inhibitor decreased the colony-forming capacity
of LICs and depleted CML in vivo (Naka et al., 2010). It will be
of interest to investigate whether the TGFb-FOXO signaling
pathway is specifically activated and required for maintaining
Sox4-mediated C/EBPa defective LICs.
Self-renewal associated signatures of both Sox4/C/EBPa
LICs and MOZ-TIF2/MLL-F9 L-GMPs share a central enzyme
of the prostaglandin E (PGE) biosynthetic pathway, Ptgs1. In
addition, our gene expression profiling analysis revealed that
not only the synthase for PGE (Ptgs1) but also the receptors
for PGE (PTGERs) exhibit increased expression in both LICs
and L-GMPs compared to their normal counterparts. This sug-
gests that this pathway or its related regulatory network might
serve as a crucial node for leukemic transformation in general.
Previous studies have suggested that PGE activated the Wnt
signaling pathway by relieving the inhibitory phosphorylation of
b-catenin (Castellone et al., 2005; Goessling et al., 2009). Inves-
tigating whether the Wnt/b-catenin pathway is commonly(E) Supervised analysis of gene expression profiles from wild-type HSCs, CMPs,
Sox4 LICs (Sox4 FRII), K/L LICs (K/L FRII), and their control counterparts, identifie
L-GMPs, but not in the LICs (fold change cutoff = 1.5; p value cutoff = 0.05).
(F) Gene set enrichment analysis demonstrated significant enrichment of the muri
(left panel, p = 0.005) or with silent CEBPA (right panel, p < 0.001) as compared
See also Figure S6, Tables S2–S4, and Table S5.
Canrequired for leukemogenic transformation, regardless of the un-
derlying initiating mutation, will be of future interest.
The findings of our mouse model are directly translatable to
human AML. SOX4 levels are strongly enhanced in human
AML patients carrying mutated or silent CEBPA, and a set of
self-renewal-associated genes that are specifically upregulated
in Sox4 and C/EBPa LICs are also highly enriched in such human
AML samples. Furthermore, human AML cells with CEBPA
deficiency recapitulate the response of murine cells to Sox4
knockdown and are driven into differentiation. Considering the
selective toxicity of Sox4 ablation to leukemic cells, but not to
normal HSCs (Schilham et al., 1996), it may therefore be a
promising target for effective and leukemia subtype-specific
therapies.
EXPERIMENTAL PROCEDURES
Serial Replating Assay
Cells were plated inMethocult M4343media (StemCell Technologies), and the
colony number was counted and subjected to replating every 10 days.
Mouse Strains
Cebpa conditional knockout mice, Sox4loxP/+ heterozygous mice, and K/L
mice have been described previously (Bereshchenko et al., 2009; Penzo-Me´n-
dez et al., 2007; Zhang et al., 2004). Sox4 conditional knockout mice were
generated by breeding Sox4loxP/+ mice to Sox4loxP/loxP homozygous mice
and intercrossing Sox4loxP/loxP mice with Mx1-Cre mice. Sox4/Cebpa
conditional double-knockout mice were generated by intercrossing the
CebpaloxP/loxP mice carrying the Mx1-Cre transgene with Sox4loxP/loxP mice.
Chromatin Immunoprecipitation
ChIP assays were performed on stem/progenitor cells (Lin-c-kit+) or myeloid
cells (Mac1+Gr1+) as described previously (Alberich-Jorda` et al., 2012). Immu-
noprecipitation was performedwith rabbit antibodies against C/EBPa (sc-61X,
Santa Cruz) or normal rabbit immunoglobulin G (12-370, Millipore). Specific re-
gions were quantified by qPCR with SYBR reagent (Bio-Rad).
Bone Marrow Transplantation
A total of 13 104 LSKs or 23 105 viral-transduced cells were transplanted into
lethally irradiated congenic B6.SJL-Ptprca mice by retro-orbital injection with
23 105 supporting bone marrow cells from unirradiated B6.SJL-Ptprca mice.
For transplantation of cells from leukemic mice, 23 103 cells of fraction I, II, or
III were transplanted into sublethally irradiated mice. Mice were monitored by
peripheral blood analysis between 2 and 6 months posttransplantation and
were considered moribund when they were severely anemic.
Human AML samples were transduced with lentiviruses for 6 hr and
immediately transplanted into sublethally irradiated (150 rads) NSG
(NOD.Cg-Prkdcscid IL2rgtm1Wjl/szJ) mice. Donor reconstitution of recipient
hematopoiesis was analyzed 5 weeks posttransplantation.
Microarray Analysis
Total RNA was purified using a QIAGEN RNeasy Plus Micro kit and cDNA was
amplified by the Nugen Ovation Pico WTA System. The cDNA library was
labeled and hybridized to Affymetrix Mouse430 2.0 chips. Robust multiarray
average was run for Cel files generated from our lab (GSE45430) or public
databases (GSE3725 and GSE24797). Integrated data were normalized using
the cross-correlation method and further log2-transformed. Subtraction of theGMPs, and MEPs, as well as those from MLL-AF9 L-GMP, MOZ-TIF2 L-GMP,
d a set of self-renewal-associated genes that show increased expression in the
ne ‘‘specific C/EBPa-Sox4 LIC signature’’ in human AML with mutated CEBPA
to other human AML with wild-type CEBPA.
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Figure 7. Abnormal Expression of SOX4 Is Correlated with Mutations of CEBPA in Human AML
(A) Expression of Sox4 levels inCebpa KO LSK cells transduced with empty virus (MIGR1) or viruses expressing wild-type human CEBPA or its mutants identified
from AML patients (22N, 22C, 10, and 128). Relative gene expression levels were determined by qPCR as % Gapdh.
(B) HEK293 cells were transfected with murine Sox4 promoter reporter and either empty vector (pCDNA3) or constructs expressing wild-type CEBPA (WT) or
CEBPA mutants. Luciferase activities were normalized to Renilla activities and are presented as percentage of the empty vector.
(C) Primary human AML patient cells #20073 and #15251 were transduced with lentiviruses carrying scrambled shRNA or human SOX4 shRNA and transplanted
into NSG mice. Five weeks later, flow cytometry analysis was performed on the human GFP+ population in the bone marrow of transplanted mice. Differentiated
myeloid cells were identified by CD15+.
(D) Morphologically distinct cells were identified byWright-Giemsa staining of donor-derived GFP+ cells from the bonemarrow of recipient mice. Scale bar, 5 mm.
Error bars indicate the mean ± SEM of three independent experiments. *p < 0.01; **p < 0.001. See also Figure S7.
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chical clustering was executed to generate the clustering tree. Human data of
AML with mutated or silent CEBPA and normal CEBPA were taken from
GSE14468 and normalized as described above. Gene set enrichment analysis
was performed as previously described (Ye et al., 2013).
Statistical Analysis
Survival analysis was performed using the Kaplan-Meier method. Differ-
ences between survival distributions were analyzed using the log-rank586 Cancer Cell 24, 575–588, November 11, 2013 ª2013 Elsevier Inctest. All other statistical analyses were performed using the unpaired Stu-
dent’s t test. Statistical computations were performed using GraphPad
Prism.
Study Approval
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